WEBVTT
Language: en-US

1
00:00:10.109 --> 00:00:12.229
<v John Lester>Hello and welcome to Buildings of
Tomorrow.

2
00:00:12.380 --> 00:00:16.309
<v John Lester>My name is John Lester, and in today's
episode we are talking about the life science

3
00:00:16.309 --> 00:00:16.389
<v John Lester>industry.

4
00:00:16.469 --> 00:00:21.389
<v John Lester>What is it and some of the really key
challenges and, and opportunities that the

5
00:00:21.389 --> 00:00:25.250
<v John Lester>life science industry have to handle and
really have the chance to take advantage

6
00:00:25.250 --> 00:00:25.670
<v John Lester>of.

7
00:00:25.989 --> 00:00:27.409
<v John Lester>I'm joined today by Chad House.

8
00:00:27.469 --> 00:00:30.870
<v John Lester>He is the head of Life Science for
Americas at Siemens Smart-Infrastructure.

9
00:00:30.989 --> 00:00:32.729
<v John Lester>Chad, thank you so much for joining us
today.

10
00:00:33.220 --> 00:00:33.819
<v Chad House>Thank you for having me,

11
00:00:33.900 --> 00:00:34.360
<v John Lester>John.

12
00:00:34.740 --> 00:00:35.659
<v John Lester>It's an absolute pleasure.

13
00:00:35.779 --> 00:00:37.599
<v John Lester>So today we're talking about life
sciences.

14
00:00:37.680 --> 00:00:41.279
<v John Lester>What do we mean when we talk about life
science or the life science industry?

15
00:00:41.659 --> 00:00:42.270
<v Chad House>Yeah, yeah.

16
00:00:42.500 --> 00:00:46.009
<v Chad House>That's a good question, John, because, you
know, there's a lot of different, uh, you

17
00:00:46.009 --> 00:00:47.540
<v Chad House>know, definitions of life science.

18
00:00:47.900 --> 00:00:53.450
<v Chad House>You know, our definition of life science
is Although, you know, Siemens classifies

19
00:00:53.450 --> 00:00:56.970
<v Chad House>us as a vertical market, you know, really
if you look at the life science market,

20
00:00:57.049 --> 00:01:01.490
<v Chad House>we're really a horizontal market, and what
I mean by that is that we really cross

21
00:01:01.490 --> 00:01:06.449
<v Chad House>over into multiple vertical markets such
as the higher education market.

22
00:01:06.529 --> 00:01:10.529
<v Chad House>You know, they do a lot of life science
labs, R&amp;D, you know, on campuses.

23
00:01:11.000 --> 00:01:15.919
<v Chad House>government type of facilities, you know,
that's the National Institutes of Health,

24
00:01:16.000 --> 00:01:19.849
<v Chad House>you know, the CDC of the world there as
well.

25
00:01:19.959 --> 00:01:24.400
<v Chad House>So, you know, those type of lab
environments as well is very critical for our

26
00:01:24.400 --> 00:01:29.540
<v Chad House>success along with, you know, local
municipalities with, you know, pharmacy or

27
00:01:30.080 --> 00:01:31.019
<v Chad House>forensics labs.

28
00:01:31.419 --> 00:01:35.709
<v Chad House>So those are often, you know, kind of
overlooked, you know, for labs and critical

29
00:01:35.709 --> 00:01:36.599
<v Chad House>environments there.

30
00:01:36.949 --> 00:01:42.190
<v Chad House>And then, you know, the the big pharma,
you know, the pharmaceutical market is a big

31
00:01:42.190 --> 00:01:45.419
<v Chad House>market for us as well, you know, that's
the, you know, the Johnson and Johnson's,

32
00:01:45.470 --> 00:01:51.989
<v Chad House>the AstraZeneca, the Pfizers of the world,
Merck, you know, just to name a few of

33
00:01:51.989 --> 00:01:54.470
<v Chad House>our key customers out there in the pharma
world.

34
00:01:54.684 --> 00:01:58.025
<v Chad House>Um, and then, you know, if you really look
at the healthcare market, I mean

35
00:01:58.025 --> 00:02:03.224
<v Chad House>healthcare is a, you know, has a lot of
lab life science pressurized spaces that,

36
00:02:03.425 --> 00:02:06.345
<v Chad House>you know, we really get involved with in
that market as well.

37
00:02:06.464 --> 00:02:10.824
<v Chad House>So that's why we consider, you know, life
science a horizontal market, you know,

38
00:02:11.104 --> 00:02:13.425
<v Chad House>within, you know, the vertical market for
life sciences.

39
00:02:14.095 --> 00:02:17.425
<v John Lester>I understand and you just mentioned a
whole lot of different applications and while

40
00:02:17.425 --> 00:02:21.570
<v John Lester>the While the space itself or the function
of some of the technology might be the

41
00:02:21.570 --> 00:02:25.600
<v John Lester>same, the applications are really, really
broad and, and probably come with their

42
00:02:25.600 --> 00:02:29.410
<v John Lester>own challenges above and beyond, you know,
the, the technical challenges that you

43
00:02:29.410 --> 00:02:30.330
<v John Lester>have to undertake.

44
00:02:30.789 --> 00:02:31.779
<v Chad House>Yes, absolutely.

45
00:02:32.669 --> 00:02:37.169
<v John Lester>You know, today we'll probably look a
little bit, we'll focus a little bit in some

46
00:02:37.169 --> 00:02:38.460
<v John Lester>of the segments of this market.

47
00:02:38.710 --> 00:02:44.639
<v John Lester>And so give us a bit of an idea when we're
talking about, you know, the The

48
00:02:44.639 --> 00:02:50.070
<v John Lester>government agencies, you know, your CDCs,
your, your WHOs, these kinds of

49
00:02:50.139 --> 00:02:54.149
<v John Lester>organizations, your large pharma
manufacturers, Pfizer, etc.

50
00:02:54.770 --> 00:02:56.270
<v John Lester>What, what are they, what are they really
up against?

51
00:02:56.360 --> 00:02:59.630
<v John Lester>What are some of the key challenges that
they find in this industry that keep them

52
00:02:59.630 --> 00:03:00.289
<v John Lester>up at night?

53
00:03:00.630 --> 00:03:04.429
<v Chad House>Yeah, yeah, that's, that's, uh, you know,
there's a lot of challenges that a lot of

54
00:03:04.429 --> 00:03:06.710
<v Chad House>our customers are facing, you know, these
days as well.

55
00:03:06.789 --> 00:03:11.610
<v Chad House>But if you look at the life science
market, The the the customers that, you know,

56
00:03:11.690 --> 00:03:16.250
<v Chad House>are into the life science market, if you
look at, they really enjoy, you know,

57
00:03:16.369 --> 00:03:19.449
<v Chad House>their, their, their spaces, their
facilities, you know, they really take a lot of

58
00:03:19.449 --> 00:03:24.250
<v Chad House>pride into their, their research spaces,
but if you look at the market, you know,

59
00:03:24.330 --> 00:03:29.250
<v Chad House>there's a lot of aging infrastructure out
there that really needs to be, you know,

60
00:03:29.449 --> 00:03:35.750
<v Chad House>taken advantage of, you know, upgrades
and, you know, bringing them up to modern

61
00:03:35.750 --> 00:03:36.750
<v Chad House>technology, you know, for today.

62
00:03:37.350 --> 00:03:42.649
<v Chad House>Um, you know, go to market faster is
another key challenge for a lot of these

63
00:03:42.649 --> 00:03:47.229
<v Chad House>customers, and what I mean by that is, you
know, just like any, any other market out

64
00:03:47.229 --> 00:03:51.589
<v Chad House>there, you know, they have to really be on
the forefront and be quick to, you know,

65
00:03:51.690 --> 00:03:53.610
<v Chad House>get out of the gate and get to market.

66
00:03:55.360 --> 00:03:59.389
<v Chad House>Of course, competition is becoming greater
between, you know, pharmaceutical

67
00:03:59.389 --> 00:04:03.289
<v Chad House>customers and, you know, life science
customers as well.

68
00:04:03.779 --> 00:04:10.580
<v Chad House>And then, you know, the big one too is
actually retracting and attracting and

69
00:04:10.580 --> 00:04:14.220
<v Chad House>retaining actually the top researchers,
you know, that really goes for, you know,

70
00:04:14.619 --> 00:04:19.540
<v Chad House>the higher education or government type of
facilities where they're trying to, you

71
00:04:19.540 --> 00:04:26.010
<v Chad House>know, They're trying to attract, you know,
the top researchers to come to their

72
00:04:26.010 --> 00:04:29.929
<v Chad House>facilities and do the research so they can
actually get, you know, the top research

73
00:04:29.929 --> 00:04:33.079
<v Chad House>grants and the and the monies that are
available there.

74
00:04:33.160 --> 00:04:33.970
<v Chad House>So how do they do that?

75
00:04:34.010 --> 00:04:37.649
<v Chad House>You know, they really have to be on their
game and they have to, you know, have

76
00:04:37.649 --> 00:04:42.589
<v Chad House>their facilities be, you know, top notch,
state of the art technology, you know, if

77
00:04:42.589 --> 00:04:46.570
<v Chad House>these top researchers have, you know, the
choice to go from one site to another

78
00:04:46.570 --> 00:04:47.049
<v Chad House>site.

79
00:04:47.339 --> 00:04:51.220
<v Chad House>You know, of course they're going to pick
probably the best looking building out

80
00:04:51.220 --> 00:04:55.940
<v Chad House>there that has the best technology out
there as opposed to, you know, one that's

81
00:04:55.940 --> 00:04:59.010
<v Chad House>maybe has antiquated technology, hasn't
been upgraded over the years.

82
00:04:59.100 --> 00:05:03.329
<v Chad House>So that's, you know, a big challenge out
there, Mark, is the big aging

83
00:05:03.329 --> 00:05:06.089
<v Chad House>infrastructure and then, you know, not to
mention, you know, it's just the

84
00:05:06.089 --> 00:05:08.459
<v Chad House>competition out there that's out there.

85
00:05:09.170 --> 00:05:12.380
<v John Lester>Yeah, and that aging infrastructure is a
difficult one because when when we're

86
00:05:12.380 --> 00:05:18.279
<v John Lester>talking about, you know, these, these
research grants, you know, these, these really

87
00:05:18.739 --> 00:05:23.820
<v John Lester>detailed, focused, and in many cases
long-term processes where they're doing

88
00:05:23.820 --> 00:05:29.739
<v John Lester>research and development, you know, you
can't compromise on the environmental space

89
00:05:29.739 --> 00:05:34.959
<v John Lester>or the integrity of the space or the
integrity of, of the process itself.

90
00:05:35.700 --> 00:05:41.209
<v John Lester>Is that That challenge must is quite a
conflicting one against you when you're

91
00:05:41.209 --> 00:05:45.359
<v John Lester>talking about aging infrastructure, when
you're talking about trying to trying to be

92
00:05:45.359 --> 00:05:46.970
<v John Lester>competitive, trying to be efficient.

93
00:05:47.679 --> 00:05:50.980
<v John Lester>When you know that you have to invest to
just go about your core day to day

94
00:05:50.980 --> 00:05:51.470
<v John Lester>business.

95
00:05:51.959 --> 00:05:52.420
<v Chad House>Correct.

96
00:05:52.679 --> 00:05:52.940
<v Chad House>Exactly.

97
00:05:53.559 --> 00:05:56.839
<v Chad House>So that's a good point there, John, as you
know, I should say, you know, if you look

98
00:05:56.839 --> 00:06:00.760
<v Chad House>at, you know, the life science research
buildings, there's a lot of different, you

99
00:06:00.760 --> 00:06:05.279
<v Chad House>know, stringent codes and standards that
apply to these type of facilities that

100
00:06:05.279 --> 00:06:09.760
<v Chad House>don't necessarily apply to, you know, a
non-lab type of facility, so.

101
00:06:10.000 --> 00:06:14.160
<v Chad House>That's another, you know, you know, they
have to maintain the compliance, you know,

102
00:06:14.440 --> 00:06:18.920
<v Chad House>to, uh, you know, you know, if a
regulatory body comes in and does an audit, you

103
00:06:18.920 --> 00:06:22.160
<v Chad House>know, they have to have proof that, you
know, they're operating these buildings in a

104
00:06:22.160 --> 00:06:27.359
<v Chad House>safe manner, number one, but, you know,
that's another challenge that I probably

105
00:06:27.359 --> 00:06:28.519
<v Chad House>kind of overlooked there.

106
00:06:29.700 --> 00:06:34.100
<v John Lester>Yeah, but it's, you know, it's kind of
intrinsic into it, so it's not, not so much

107
00:06:34.100 --> 00:06:37.250
<v John Lester>overlooking, but it's, it's for them, it's
standard operating procedure no matter

108
00:06:37.250 --> 00:06:41.260
<v John Lester>what they're doing, no matter what they're
creating, it's kind of, it's a base

109
00:06:41.260 --> 00:06:45.779
<v John Lester>platform of minimum requirement that has
to be fulfilled, which is, which is not so

110
00:06:45.779 --> 00:06:48.000
<v John Lester>easy to achieve perhaps in some cases.

111
00:06:49.660 --> 00:06:54.500
<v John Lester>So, so I'd like to dive a little bit more
into this time to market because that's an

112
00:06:54.500 --> 00:06:58.260
<v John Lester>interesting one that's, you know, and,
and, and all of us in the, in the world have

113
00:06:58.260 --> 00:07:03.019
<v John Lester>kind of been living, we've been following
a research development, you know,

114
00:07:03.299 --> 00:07:09.459
<v John Lester>production and rollout phase or process in
the life science market maybe like we've

115
00:07:09.459 --> 00:07:13.279
<v John Lester>never done before when we've talked about
vaccinations for COVID, you know, we,

116
00:07:13.820 --> 00:07:14.359
<v John Lester>we've seen.

117
00:07:14.929 --> 00:07:19.970
<v John Lester>So much effort going in from some of these
companies you mentioned before, from

118
00:07:19.970 --> 00:07:23.450
<v John Lester>March last year through to now when there
are millions of doses running around the

119
00:07:23.450 --> 00:07:23.910
<v John Lester>world.

120
00:07:24.369 --> 00:07:28.019
<v John Lester>Uh, you know, what, what are some of, if
we dive into that time to market, what are

121
00:07:28.019 --> 00:07:32.619
<v John Lester>some of the real challenges about, about
achieving that, and, and what are some of

122
00:07:32.619 --> 00:07:37.660
<v John Lester>the phases that a company has to go
through before we get that, that, uh, that

123
00:07:37.660 --> 00:07:38.769
<v John Lester>product in our hands?

124
00:07:39.019 --> 00:07:39.299
<v John Lester>Yeah,

125
00:07:39.459 --> 00:07:39.730
<v Chad House>yeah.

126
00:07:40.100 --> 00:07:43.980
<v Chad House>So yeah, if you look at, you know, what
we've just, you know, have been through with

127
00:07:43.980 --> 00:07:48.570
<v Chad House>COVID, you know, in particular is You
know, really the time the market was really

128
00:07:48.570 --> 00:07:50.609
<v Chad House>accelerated just because it had to be,
right?

129
00:07:50.690 --> 00:07:56.130
<v Chad House>They had to, you know, come up with a
vaccine in a quick, you know, manner there to

130
00:07:56.130 --> 00:07:57.089
<v Chad House>overcome this pandemic.

131
00:07:57.200 --> 00:08:01.760
<v Chad House>But just in general, if you look at the
life science market, you know, we tend to be

132
00:08:01.760 --> 00:08:04.100
<v Chad House>both pandemic and recession proof.

133
00:08:04.649 --> 00:08:08.000
<v Chad House>So, you know, life science is really kind
of we can weather through the storm, you

134
00:08:08.000 --> 00:08:11.329
<v Chad House>know, even if, you know, other markets
tend to be down, you know, some of our

135
00:08:11.329 --> 00:08:15.609
<v Chad House>markets were down over the last couple of
years in particular with the pandemic.

136
00:08:16.209 --> 00:08:21.350
<v Chad House>But you know, the time the market is
critical for these guys because if you look at,

137
00:08:21.630 --> 00:08:26.380
<v Chad House>you know, typical, you know, research and
development, it can take, you know, 58,

138
00:08:26.589 --> 00:08:31.500
<v Chad House>you know, 10 years to develop a particular
vaccine or a medicine there, but with

139
00:08:31.500 --> 00:08:34.070
<v Chad House>COVID they didn't have that luxury of that
time, right?

140
00:08:34.109 --> 00:08:39.190
<v Chad House>So they actually had to get out there and
do the research and, you know, run it

141
00:08:39.190 --> 00:08:44.580
<v Chad House>through the testing phases and get it to
market quicker, quick as possible, so.

142
00:08:44.809 --> 00:08:48.919
<v Chad House>You probably, you know, saw that, you
know, Pfizer was one of them, Johnson and

143
00:08:48.919 --> 00:08:53.929
<v Chad House>Johnson, Moderna, you know, were the first
three kind of out of the gate there, so

144
00:08:53.929 --> 00:08:58.570
<v Chad House>it was kind of a race, but, you know, more
interesting is too is we saw a lot of

145
00:08:58.570 --> 00:09:03.880
<v Chad House>these companies form partnerships that you
typically don't, you know, see out there,

146
00:09:03.929 --> 00:09:08.539
<v Chad House>you know, you know, we see competitors
coming together and form partnerships to You

147
00:09:08.539 --> 00:09:14.700
<v Chad House>know, get the vaccine out to market, you
know, faster to overcome the

148
00:09:15.099 --> 00:09:18.159
<v Chad House>challenges that we were faced with the
COVID pandemic.

149
00:09:20.179 --> 00:09:24.780
<v Chad House>I think we have a lot to offer if you look
at, you know, Siemens in general, um, you

150
00:09:24.780 --> 00:09:28.820
<v Chad House>know, hands down, you know, the
capabilities that Siemens can provide our customers

151
00:09:28.820 --> 00:09:32.489
<v Chad House>with, you know, as far as the
digitalization, we can help them, uh, you know,

152
00:09:32.900 --> 00:09:37.559
<v Chad House>automate their facilities and have them
work more efficiently and effectively.

153
00:09:38.000 --> 00:09:42.150
<v Chad House>Um, while, you know, keeping that facility
in a safe, compliant manner as well.

154
00:09:42.349 --> 00:09:47.190
<v Chad House>So, you know, the digitalization for, you
know, the, the capabilities that we have

155
00:09:47.190 --> 00:09:51.630
<v Chad House>with our digitalization capabilities, you
know, is you're really hands down compared

156
00:09:51.630 --> 00:09:55.390
<v Chad House>to our competitors out there, you know,
you know, they, they, our competitors really

157
00:09:55.390 --> 00:09:57.150
<v Chad House>can't compete with us on there.

158
00:09:57.190 --> 00:10:02.190
<v Chad House>So we're really in a unique position, you
know, to help our customers get to market

159
00:10:02.190 --> 00:10:08.390
<v Chad House>faster and Um, and you know, build that
strategy, you know, and we can actually look

160
00:10:08.390 --> 00:10:13.450
<v Chad House>at, you know, further expanding our
capabilities with, you know, standardization,

161
00:10:13.710 --> 00:10:17.619
<v Chad House>you know, so we're not recreating a wheel
for every type of project out there.

162
00:10:17.989 --> 00:10:23.539
<v Chad House>So with our standardization with our
engineering and startup procedures, you know,

163
00:10:23.590 --> 00:10:27.710
<v Chad House>that really saves a lot of time and
actually money too, so we can actually be a lot

164
00:10:27.710 --> 00:10:30.570
<v Chad House>more cost effective compared to our
competitors.

165
00:10:31.229 --> 00:10:31.849
<v John Lester>Yeah, I understand.

166
00:10:32.289 --> 00:10:35.539
<v John Lester>Uh, let's jump back to the time to market
a little bit because you mentioned there

167
00:10:35.539 --> 00:10:41.530
<v John Lester>58, 10 years, you know, spending this
amount of time on developing a product, can't

168
00:10:41.530 --> 00:10:42.520
<v John Lester>be a cheap process.

169
00:10:43.219 --> 00:10:49.780
<v John Lester>Uh, how do, you know, normally when you
talk about this, this investment into

170
00:10:49.780 --> 00:10:53.219
<v John Lester>research and development, we then talk
about, OK, you've got a product, how, how

171
00:10:53.219 --> 00:10:54.219
<v John Lester>long can you be unique?

172
00:10:54.299 --> 00:10:55.650
<v John Lester>How long can you leverage that?

173
00:10:56.419 --> 00:10:59.739
<v John Lester>How does it look in the life science
market when they, when they develop these

174
00:10:59.739 --> 00:11:02.989
<v John Lester>products, they invest so much time and
effort and money into it.

175
00:11:03.539 --> 00:11:08.460
<v John Lester>How does the time the market really affect
their ability to, to then realize the

176
00:11:08.460 --> 00:11:08.880
<v John Lester>opportunity?

177
00:11:09.900 --> 00:11:14.909
<v Chad House>So that's critical for, you know,
especially the large, large pharma when they spend

178
00:11:14.909 --> 00:11:21.070
<v Chad House>the money to for the R&amp;D on these new
vaccines, new drugs, you know, new medicines

179
00:11:21.070 --> 00:11:21.659
<v Chad House>out there.

180
00:11:21.989 --> 00:11:28.590
<v Chad House>Really they have a short window to get it
to market and take advantage of, you know,

181
00:11:28.700 --> 00:11:32.510
<v Chad House>and kind of recoup their R&amp;D costs
before, you know, their patent runs out.

182
00:11:32.619 --> 00:11:34.190
<v Chad House>You know, they actually have to file
patents.

183
00:11:34.510 --> 00:11:40.349
<v Chad House>And it's a very short window for, you
know, that patent window that expires, and

184
00:11:40.349 --> 00:11:43.909
<v Chad House>then that actually gives the opportunity
for, you know, the generic companies, you

185
00:11:43.909 --> 00:11:50.270
<v Chad House>know, the smaller companies to come in and
develop a generic type of drug to be a

186
00:11:50.270 --> 00:11:56.270
<v Chad House>cost effective option for that those that
R&amp;D that they've actually expended, you

187
00:11:56.270 --> 00:12:00.030
<v Chad House>know, billions of dollars on, you know, a
lot of times in this case is so.

188
00:12:00.280 --> 00:12:05.159
<v Chad House>It's really critical, you know, for them
to, you know, get their R&amp;D done, run it

189
00:12:05.159 --> 00:12:09.679
<v Chad House>through the testing phase, and, you know,
get it to market and, you know, try to

190
00:12:09.679 --> 00:12:14.919
<v Chad House>recoup as much cost as they can before,
you know, the patent runs out and these

191
00:12:15.719 --> 00:12:19.840
<v Chad House>generic companies come in and take
advantage of the window that they have to develop

192
00:12:19.840 --> 00:12:20.780
<v Chad House>a generic option.

193
00:12:21.309 --> 00:12:25.169
<v John Lester>Yeah, right, so you put all this effort
in, you have this really short window where

194
00:12:25.169 --> 00:12:29.250
<v John Lester>you kind of have exclusivity in the market
to a certain extent, correct.

195
00:12:29.349 --> 00:12:33.830
<v John Lester>And once that expires, then you have a
challenge because of course there are others

196
00:12:33.830 --> 00:12:36.909
<v John Lester>that can do things differently or in a
different place or whatever it might be.

197
00:12:37.309 --> 00:12:40.109
<v John Lester>And this brings us back to one of the
points you raised before around that

198
00:12:40.109 --> 00:12:42.250
<v John Lester>digitalization and that flexibility.

199
00:12:42.669 --> 00:12:49.200
<v John Lester>And the speed in adopting because you have
to be able to to redeploy a facility that

200
00:12:49.200 --> 00:12:54.840
<v John Lester>maybe was making product A yesterday,
needs to make product B by in volume, you

201
00:12:54.840 --> 00:13:00.179
<v John Lester>know, industrial volumes tomorrow, and the
shortest period of time between A and B

202
00:13:00.840 --> 00:13:05.780
<v John Lester>has a huge effect on the ability for that
company to take advantage from that.

203
00:13:06.840 --> 00:13:08.630
<v John Lester>How, how does that work?

204
00:13:09.000 --> 00:13:12.799
<v John Lester>What, what are the challenges within that
kind of process from changing from, you

205
00:13:12.799 --> 00:13:16.440
<v John Lester>know, redeploying that or, uh, uh, you
know, bringing something online, a

206
00:13:16.440 --> 00:13:22.059
<v John Lester>manufacturing facility for a new product,
and how can that digitalization aspect

207
00:13:22.479 --> 00:13:26.400
<v John Lester>facilitate the speed and facilitate the
accuracy while maintaining, maintaining all

208
00:13:26.400 --> 00:13:29.380
<v John Lester>of the regulatory and, and safety
requirements.

209
00:13:30.690 --> 00:13:34.849
<v Chad House>So you know with our digitalization
capabilities, you know, we can really, you know,

210
00:13:35.169 --> 00:13:41.090
<v Chad House>assist our customers with, you know,
keeping on track and making their operation and

211
00:13:41.090 --> 00:13:45.849
<v Chad House>their production operation more efficient,
you know, at that more so that allows

212
00:13:45.849 --> 00:13:46.549
<v Chad House>them to.

213
00:13:47.250 --> 00:13:53.840
<v Chad House>get their, their product out to the market
quicker and take advantage of

214
00:13:53.840 --> 00:14:00.479
<v Chad House>the, the, the added time factor that's,
you know, that is realized there with taking

215
00:14:00.479 --> 00:14:06.039
<v Chad House>advantage of technology for the
efficiencies, but not, not, not to mention, you

216
00:14:06.039 --> 00:14:10.229
<v Chad House>know, as far as the compliance tracking,
you know, with the digitalization that we

217
00:14:10.229 --> 00:14:13.919
<v Chad House>can do and help our customers with, you
know, we can actually provide, you know, the

218
00:14:13.919 --> 00:14:14.539
<v Chad House>electronic.

219
00:14:16.419 --> 00:14:22.780
<v Chad House>Records that you know are required by
these regulatory bodies to, you know, to prove

220
00:14:22.780 --> 00:14:28.099
<v Chad House>that we're, you know, producing these
products in a safe manner, number one, you

221
00:14:28.099 --> 00:14:28.580
<v Chad House>know, that's key.

222
00:14:28.700 --> 00:14:35.140
<v Chad House>Number one is you can't compromise safety
to improve efficiency and the operation of

223
00:14:35.140 --> 00:14:35.570
<v Chad House>the facility.

224
00:14:35.599 --> 00:14:37.539
<v Chad House>I mean, safety is still number one.

225
00:14:37.820 --> 00:14:40.479
<v Chad House>You hear about it in the market all the
time where, you know, some of these large

226
00:14:41.260 --> 00:14:42.039
<v Chad House>drug companies.

227
00:14:42.570 --> 00:14:46.489
<v Chad House>They actually have, you know, an issue
with their production, and they actually have

228
00:14:46.489 --> 00:14:50.489
<v Chad House>to actually dispose of a lot of their
product, which is a lot of money, you know,

229
00:14:50.609 --> 00:14:51.969
<v Chad House>that's wasted at that point.

230
00:14:52.090 --> 00:14:56.080
<v Chad House>So how, you know, with our digitalization,
we can actually, you know, help our

231
00:14:56.080 --> 00:15:02.169
<v Chad House>customers, um, be more effective and
efficient and, you know, track, you know, the

232
00:15:02.169 --> 00:15:05.349
<v Chad House>progress of the manufacturing process
there as well.

233
00:15:05.869 --> 00:15:10.150
<v John Lester>Yeah, and mitigate that risk because as
you say you're turning something that could

234
00:15:10.150 --> 00:15:16.630
<v John Lester>be a valuable product into just a
liability and, and that, you know, the difference

235
00:15:16.630 --> 00:15:20.150
<v John Lester>between throwing out everything you did in
a day compared to everything you did

236
00:15:20.150 --> 00:15:24.130
<v John Lester>between the 6 minutes or something like
that can have a huge impact then on huge,

237
00:15:25.419 --> 00:15:26.349
<v Chad House>yes, yep, huge.

238
00:15:27.460 --> 00:15:28.000
<v John Lester>Perfect.

239
00:15:28.400 --> 00:15:32.000
<v John Lester>Chad, thank you so much, uh, for this
insight into the life science market.

240
00:15:32.159 --> 00:15:35.250
<v John Lester>Uh, I, I'm excited to talk to you a little
bit more about some of the really

241
00:15:35.250 --> 00:15:39.479
<v John Lester>specific details here because as we talked
about right at the start, you know, some

242
00:15:39.479 --> 00:15:43.679
<v John Lester>of these, these, uh, these companies, some
of these processes like you discussed,

243
00:15:44.080 --> 00:15:47.440
<v John Lester>these are kind of daily, you know, they're
household names for us somehow, uh, and

244
00:15:47.440 --> 00:15:52.320
<v John Lester>it's interesting to understand the
challenges that they overcome to, To create and

245
00:15:52.320 --> 00:15:56.599
<v John Lester>deliver some of these, you know, these
products, whether it be from big pharma or

246
00:15:56.599 --> 00:16:02.049
<v John Lester>protecting us, you know, from a CDC or a
WHO perspective or, or

247
00:16:02.049 --> 00:16:05.640
<v John Lester>in those forensic applications,
laboratories in hospitals and all these kinds of

248
00:16:05.640 --> 00:16:07.760
<v John Lester>things, I think it's, it's really
interesting.

249
00:16:07.820 --> 00:16:10.020
<v John Lester>So thank you so much for the time and
thanks for joining us.

250
00:16:10.530 --> 00:16:14.739
<v Chad House>Thank you for the opportunity and I look
forward to, you know, definitely further

251
00:16:14.739 --> 00:16:16.109
<v Chad House>conversations with you folks.

252
00:16:16.460 --> 00:16:17.460
<v John Lester>Bring it on, bring it on.

253
00:16:17.659 --> 00:16:19.799
<v John Lester>And thank you to everyone who's listening
to us as well.

254
00:16:20.299 --> 00:16:22.599
<v John Lester>Remember to share, like, comment on this
episode.

255
00:16:23.020 --> 00:16:26.859
<v John Lester>Subscribe to us whether you're listening
to us via one of your preferred podcast

256
00:16:26.859 --> 00:16:28.780
<v John Lester>channels or watching this video on
YouTube.

257
00:16:29.150 --> 00:16:30.090
<v John Lester>Uh, check us out.

258
00:16:30.229 --> 00:16:34.710
<v John Lester>There's new episodes every week after a
little bit of a break over our Northern

259
00:16:34.710 --> 00:16:35.510
<v John Lester>Hemisphere summer.

260
00:16:35.859 --> 00:16:40.010
<v John Lester>But, uh, remember to keep your eye out for
new, uh, technologies and, and new

261
00:16:40.010 --> 00:16:41.190
<v John Lester>conversations with Chad in the near
future.

262
00:16:41.349 --> 00:16:41.969
<v John Lester>Thank you all.
